Johnson & Johnson buy UBS Group AG
Start price
17.07.25
/
50%
€140.40
Target price
17.07.26
€163.46
Performance (%)
57.59%
End price
18.07.26
€221.25
Summary
This prediction ended on 18.07.26 with a price of €221.25. With a performance of 57.59% the BUY prediction by UBS_Group_AG was a big success. UBS_Group_AG has a follow-up prediction for Johnson & Johnson where he still thinks Johnson & Johnson is a Buy. UBS_Group_AG has 50% into this predictionJohnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Johnson & Johnson | 6.550% | 6.550% | 63.354% |
| iShares Core DAX® | 1,72 % | 3,37 % | 5,89 % |
| iShares Nasdaq 100 | -4,56 % | -4,24 % | 21,39 % |
| iShares Nikkei 225® | -7,12 % | -11,87 % | 42,36 % |
| iShares S&P 500 | -0,89 % | 1,69 % | 19,49 % |
Comments by UBS_Group_AG for this prediction
In the thread Johnson & Johnson diskutieren
Johnson & Johnson (NYSE: JNJ) had its price target raised by analysts at UBS Group AG from $180.00 to $190.00. They now have a "buy" rating on the stock.
Ratings data for JNJ provided by MarketBeat
In the thread Trading Johnson & Johnson
Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten
Current prediction by UBS_Group_AG for Johnson & Johnson
Stopped prediction by UBS_Group_AG for Johnson & Johnson
Johnson & Johnson
Start price
Target price
Perf. (%)
€143.60
01.12.23
01.12.23
€165.58
01.12.24
01.12.24
2.05%
02.12.24
02.12.24
